^
    Back
    Association details:
    Biomarker:RET fusion
    Cancer:Thyroid Gland Papillary Carcinoma
    Drug:Retevmo (selpercatinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Papillary Thyroid Cancer: Consider systemic therapy…Selpercatinib for patients with RET-fusion positive tumor
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for )
    New
    Title:

    The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers

    Excerpt:
    Innovent Biologics, Inc...is pleased to see that the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA) for selpercatinib (40mg & 80mg capsules) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A prospective, non-interventional, post-marketing observational study evaluating the efficacy and safety of selpercatinib capsules in adults and children with advanced or metastatic RET gene fusion-positive thyroid cancer.

    Excerpt:
    ......
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

    Excerpt:
    ...- Participants must have histologically- or cytologically-confirmed follicular-derived nonanaplastic thyroid cancer that is metastatic and/or unresectable AND harbors a known oncogenic RET gene fusion, performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalently accredited diagnostic laboratory....
    Trial ID:
    NCT05668962
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.

    Published date:
    05/16/2018
    Excerpt:
    ...RET fusion+ NSCLC and papillary thyroid cancer (PTC), RET-mutant medullary thyroid cancer (MTC)...The ORR in evaluable RET fusion+ pts was...65% (n = 17/26) in NSCLC and 83% (n = 5/6) in PTC.
    DOI:
    10.1200/JCO.2018.36.15_suppl.102
    Trial ID:
    LIBRETTO-001